Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded and Fucosylated Cord Blood Transplant for Hematologic Malignancies
NCT03096782Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- Sep 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord blood-derived regulatory T cells in hematologic malignancy, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2017; status: completed.
02
Drugs
umbilical cord blood-derived regulatory T cells
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03096782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096782.